文章摘要
邹华,刘春磊.经皮椎体成形术治疗慢性阻塞性肺疾病合并骨质疏松椎体骨折的临床研究.骨科,2022,13(2): 121-124.
经皮椎体成形术治疗慢性阻塞性肺疾病合并骨质疏松椎体骨折的临床研究
Percutaneous Vertebroplasty in the Treatment of Chronic Obstructive Pulmonary Disease Combined with Osteoporotic Vertebral Compression Fractures
投稿时间:2021-10-21  
DOI:10.3969/j.issn.1674-8573.2022.02.005
中文关键词: 慢性阻塞性肺疾病  椎体压缩性骨折  骨质疏松  治疗结果
英文关键词: Chronic obstructive pulmonary disease  Vertebral compression fracture  Osteoporosis  Treatment outcome
基金项目:2019年度清远市社会发展领域科技计划立项项目(2019150)
作者单位E-mail
邹华 广州医科大学附属第六医院(清远市人民医院)呼吸科广东清远 511518  
刘春磊 广州医科大学附属第六医院(清远市人民医院)骨科广东清远 511518 liuchunlei382868@163.com 
摘要点击次数: 2227
全文下载次数: 2191
中文摘要:
      目的 观察经皮椎体成形术治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)合并骨质疏松椎体骨折的临床疗效。方法 回顾分析126例COPD合并骨质疏松椎体骨折病人的临床资料,常规治疗的78例纳入常规治疗组,行经皮椎体成形术治疗的48例纳入椎体成形组。比较分析两组病人治疗前后的疼痛视觉模拟量表(visual analogue scale,VAS)评分、Oswestry功能障碍指数(Oswestry disability index,ODI)、肺活量(VC)、用力肺活量(FVC)、第一秒用力呼气容积(FEV1)及每分钟最大通气量(MVV)。结果 椎体成形组的住院时间为(5.16±1.48) d,与常规治疗组的(10.23±2.32) d比较,差异有统计学意义(P<0.05)。治疗后1周和1个月时,椎体成形组的VAS评分、ODI指数、VC、FVC、FEV1、MVV的改善值均较常规治疗组明显提高,差异有统计学意义(P<0.05);但两组治疗后1年时的改善值未见明显差异。椎体成形组治疗后1年内椎体再发骨折率为16.7%(8/48),较常规治疗组的35.9%(28/78)低,差异有统计学意义(P=0.020)。结论 经皮椎体成形术治疗COPD合并骨质疏松椎体骨折住院时间短,可改善早期疼痛及肺功能,椎体再发骨折率低,如无手术禁忌,建议尽早行经皮椎体成形手术。
英文摘要:
      Objective To observe the clinical effect of percutaneous vertebroplasty in the treatment of chronic obstructive pulmonary disease (COPD) combined with osteoporosis vertebral compression fractures. Methods The clinical data of 126 cases of COPD combined with osteoporosis vertebral compression fractures were retrospectively analyzed, including 78 cases in the conventional treatment group and 48 cases in the vertebroplasty group. The visual analogue scale (VAS) score, Oswestry disability index (ODI), vital capacity (VC), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and maximum volume per minute (MVV) before and after treatment between the two groups were compared. Results The hospitalization time of vertebroplasty group was (5.16±1.48) d, which was significantly longer than that of conventional treatment group [(10.23±2.32) d, (P<0.05)]. The VAS, ODI, VC, FVC, FEV1 and MVV scores improvement of the percutaneous vertebroplasty group were better than those of the conservative treatment group at 1 week, 1 month after surgery, and the difference was statistically significant (P<0.05). However, there was no significant difference in all scores improvement between two groups at 1 year after treatment. The recurrence rate of vertebral fracture in the percutaneous vertebroplasty group was 16.7% (8/48), lower than that in the conservative treatment group [35.9% (28/78)] one year post-discharge, and the difference was statistically significant (P=0.020). Conclusion Percutaneous vertebroplasty in the treatment of COPD combined with osteoporosis vertebral compression fracture exerts short course of disease, obvious improvement of pain and pulmonary function, low rate of vertebral recurrence fracture. If there is no surgical contraindication, percutaneous vertebroplasty is recommended as early as possible.
查看全文   下载PDF阅读器
关闭